Live Breaking News & Updates on Least One Phase

Stay updated with breaking news from Least one phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Neurocrine Biosciences Reports First Quarter 2023 Financial Results

/PRNewswire/ Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2023 and provided an. ....

United States , Neurocrine Bioscience , Neurocrine Biosciences , Kevin Gorman , Prnewswire Neurocrine Biosciences Inc , Xenon Pharmaceuticals , Voyager Therapeutics Inc , Takeda Pharmaceutical Company , Sosei Group Corporation , Mitsubishi Tanabe Pharma Corporation , Neurocrine Biosciences Inc , First Quarter Net Product Sales , Product Sales Guidance Reiterated , Chief Executive Officer , Product Sales Highlights , Quarter Financial Highlights , Voyager Therapeutics , Updated Operating Expense Guidance , Product Sales , Pipeline Milestones , Adrenal Hyperplasia , Line Registrational Data , Onset Seizure , Line Phase , Major Depressive , Least One Phase ,

Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides Financial Expectations for 2023

/PRNewswire/ Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the fourth quarter and fiscal year ended December 31,. ....

United States , United Kingdom , Neurocrine Biosciences , Sosei Heptares , Neurocrine Bioscience , Kevin Gorman , Neurocrine Biosciences Inc , Sosei Group Corporation , Voyager Therapeutics Inc , Mitsubishi Tanabe Pharma Corporation , Drug Administration , Takeda Pharmaceutical Company , Xenon Pharmaceuticals , Diurnal Group , Fourth Quarter Net Product Sales , Product Sales Guidance , Pediatric Registrational Studies , Congenital Adrenal , Online Data , Clinical Programs , Congenital Adrenal Hyperplasia , Focal Onset Seizure , Major Depressive Disorder Expected , Second Half , Chief Executive Officer , Quarterand Fiscal ,